Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Autologous T Cell Vaccine (TCV) for Multiple Sclerosis (TERMS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Opexa Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT00245622
First received: October 20, 2005
Last updated: February 6, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2008
  Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: June 27, 2011
Publications:
Fox E, Markowitz C, Cohan S, Wynn D. TERMS Trial TCV Secondary Analysis of Clinical and Immunological Outcoms in Patients with Relapsing Remitting MS. Poster presentation P06.132 at the 61st Annual Meeting of the American Academy of Neurology (AAN) on 01 May 2009.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):